Keywords: Almirall, Forest Labs, COPD, Acidiniu, Eklira, Tudorza Pressair, Menarini
US FDA delays approval of Almirall and Forest Laboratories' COPD drug
Article | 30 March 2012
The US Food and Drug Administration has said it will require a three-month extension to complete its review of the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
